RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?
RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?
复制标题
DOI：
10.1158/1078-0432.ccr-17-3597
复制
发表时间：
2018-03-15
期刊：
影响因子：
--
通讯作者：
Barbie DA
中科院分区：
文献类型：
--
作者：
Kitajima S;Barbie DA
尽管 NF1 突变已在非小细胞肺癌 (NSCLC) 中得到描述，但与另一种 Ras-GTP 酶激活蛋白 (RasGAP) RASA1 的共突变定义了一种新的基因定义的 NSCLC 亚类。 RASA1/NF1 突变细胞系对 MEK 抑制剂高度敏感，需要对这一亚类患者的 MAPK 抑制进行临床评估。
Although mutation of NF1 has been described in non-small cell lung cancer (NSCLC), co-mutation with RASA1, another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. RASA1/NF1 mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients.